Article type : Original Article

**[Title page]**

# Risks associated with discontinuation of oral anticoagulation in newly diagnosed patients with atrial fibrillation: Results from the GARFIELD-AF Registry

**Authors:** Frank Cools[1], Dana Johnson[2], A. John Camm[3], Jean-Pierre Bassand[4,5], Freek W.A. Verheugt[6], Shu Yang[7], Anastasios Tsiatis[7], David A. Fitzmaurice[8], Samuel Z. Goldhaber[9], Gloria Kayani,[4] Shinya Goto[10], Sylvia Haas[11], Frank Misselwitz[12], Alexander G.G. Turpie[13], Keith A.A. Fox[14], Karen S Pieper[4,15], Ajay K. Kakkar[4,16], for the GARFIELD-AF Investigators*

1. AZ Klina, Brasschaat, Belgium
2. Department of Statistics, North Carolina State University, Raleigh, NC, USA
3. Cardiovascular Clinical Academic Group, St. George's University of London, London, UK
4. Thrombosis Research Institute, London, UK
5. University of Besançon, Besançon, France
6. Onze Lieve Vrouwe Gasthuis (OLVG), Amsterdam, The Netherlands
7. North Carolina State University, Raleigh, NC, USA
8. University of Warwick Medical School, UK
9. Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
10. Tokai University, Kanagawa, Japan
11. Formerly Department of Medicine, Technical University of Munich, Munich, Germany
12. Bayer HealthCare Pharmaceuticals, Berlin, Germany
13. McMaster University, Hamilton, Canada
14. Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK
15. Duke Clinical Research Institute, Durham, NC, USA
16. University College London, London, UK

*A complete list of investigators is given in the Appendix

Clinical Trial Registration - URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362.

**Corresponding author:**
Frank Cools, MD, FESC
AZ Klina, Department of Cardiology,
Augustijnslei 100, 2930 Brasschaat, Belgium.
Tel. +32 3 6505054
Email: frank.cools@klina.be

**Running head:** Discontinuing anticoagulation in atrial fibrillation (47/50)
**Word count:** 3,131/5000
**Figures/Tables:** 8/8
**References:** 41/75

**Essentials:**

- Atrial fibrillation (AF) patients exhibit a high rates of oral anticoagulation (OAC) discontinuation.
- GARFIELD-AF, a large, global prospective registry of atrial fibrillation patients.
- Discontinuation of OAC for ≥7 consecutive days is associated with higher risks of death, stroke/ systemic embolism, or myocardial infarction.
- Oral anticoagulation discontinuation should be discouraged, even for periods as short as 7 days.

**Abstract**

**Background:** Oral anticoagulation (OAC) in atrial fibrillation (AF) reduces the risk of stroke/systemic embolism (SE). The impact of OAC discontinuation is less well documented.

**Objective:** Investigate outcomes of patients prospectively enrolled in GARFIELD-AF who discontinued OAC.

**Methods**: OAC discontinuation was defined as cessation of treatment for ≥7 consecutive days. Adjusted outcome risks were assessed in 23,882 patients with 511 days of median follow-up after discontinuation.

**Results and conclusions**: Patients who discontinued (n=3,114, 13.0%) had a higher risk (Hazard ratio [95% CI]) of all-cause death (1.62 [1.25-2.09]), stroke/systemic embolism (SE) (2.21 [1.42-3.44]) and myocardial infarction (MI) (1.85 [1.09-3.13]) than patients who did not, whether OAC was restarted or not. This higher risk of outcomes after discontinuation was similar for patients treated with vitamin K antagonists (VKA) and direct oral anticoagulants (DOACs) (p for interactions range=0.145-0.778). Bleeding history (1.43 [1.14-1.80]), paroxysmal vs. persistent AF (1.15 [1.02-1.29]), emergency room care setting vs. office (1.37 [1.18-1.59]), major, clinically relevant non-major, and minor bleeding (10.02 [7.19-13.98], 2.70 [2.24-3.25] and 1.90 [1.61-2.23]), stroke/SE (4.09 [2.55-6.56]), MI (2.74 [1.69-4.43]), and left atrial appendage procedures (4.99 [1.82-13.70]) were predictors of discontinuation. Age (0.84 [0.81-0.88], per 10-year increase), history of stroke/TIA (0.81 [0.71-0.93]), diabetes (0.88 [0.80-0.97]), weeks from AF onset to treatment (0.96 [0.93-0.99] per week), and permanent vs. persistent AF (0.73 [0.63-0.86]) were predictors of lower discontinuation rates. Discontinuation for ≥7 consecutive days was associated with significantly higher all-cause mortality, stroke/SE and MI risk. Caution should be exerted when considering any OAC discontinuation beyond 7 days.

**Word count: 242/250**

**Key Words:** Anticoagulation; antiplatelet; atrial fibrillation; discontinuation; marginal structure models; outcomes

**Key questions:**

1. **What is already known on this subject?** Patients treated with oral anticoagulation have high rates of discontinuation. The impact on clinical outcome of discontinuation is less clear because prospective data are lacking.

2. **What does this study add?** Discontinuation of oral anticoagulation in patients with atrial fibrillation for ≥7 consecutive days is associated with significantly higher risks for death, stroke, systemic embolism or myocardial infarction. Discontinuation rates in this large prospective registry study are lower compared to many other studies. All types of bleeding episodes, as well as thrombotic events, are significantly associated with discontinuation.
3. **How might this impact on clinical practice?** Discontinuation of oral anticoagulation should be discouraged. This applies to VKA as well as DOACs.

**Introduction**

Oral anticoagulation (OAC) has a major impact on the outcomes of patients with atrial fibrillation (AF)[1]. Both vitamin-K antagonists (VKA) and the newer direct oral anticoagulants (DOACs) are strongly recommended by stroke prevention guidelines for patients with high risk AF[2]. Nevertheless, past studies suggest that anticoagulants are often under-prescribed[3, 4], with high rates of discontinuation (ranging from 26 to 55% at 1-year), [5, 6] due in part to the limitations associated with VKA treatment. More recently, substantial discontinuation rates ranging from 21 to 34%[7-10] during follow-up in clinical trials, and 16 to 53% in real-world studies[11-14] at 6-24 months, have also been recorded with DOAC usage, despite their ease of use and superior safety profile compared with VKAs such as warfarin[15].

Few studies have explored the relationship between OAC discontinuation and clinical outcomes. In this report, the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) collects starting and finishing dates of treatment which, unlike other databases, gives precise data regarding timing of treatment relative to outcomes. We assessed risk factors for discontinuing oral anticoagulants and its impact on clinical outcomes among 23,882 AF patients who were prescribed either VKA or DOACs for stroke prevention at the time of enrolment into GARFIELD-AF. All patients had a recent newly diagnosed AF and were followed prospectively for 2 years.

**Methods**

The design of the GARFIELD-AF registry has been reported previously[16]. In total, 52,014 patients of ≥18 years with non-valvular AF (diagnosed within the previous 6 weeks), and at least one non pre-specified risk factor for stroke (judged by the local investigator) were eligible for inclusion[16]. Patients were enrolled prospectively from representative centres in 35 countries between May 2013 and August 2016. Intended minimum follow-up was 2 years[16]. All follow-up beyond 2 years was truncated at 24-months. Data for this report were extracted from the study database on June 2019. This analysis involved patients with OAC usage from cohorts 3-5 only, because the exact treatment start and stop dates were recorded from cohort 3 onwards.

*Ethics statement*

The registry was conducted in accordance with the principles of the Declaration of Helsinki, local regulatory requirements, and the International Conference on Harmonization–Good Pharmacoepidemiologic and Clinical Practice guidelines. Independent ethics committee and hospital-based institutional review board approvals were obtained. Written informed consent was obtained from participants.

*Procedures and outcome measures*

Collection of follow-up data occurred at 4-monthly intervals up to 24-months[16]. In accordance with the study protocol, 20% of all electronic case report forms were monitored against source documentation[17]. Timing of treatment is based upon the date treatment was started and the date treatment was discontinued. Changes in treatment type were recorded. Defining discontinuation based solely on stopping and never restarting a drug in a study where patients die or stop follow-up at different points will likely produce biased results. For example, Patient A stops drug and dies two days later. Patient B stops drug and restarts 3 days later. Patient A would be defined as discontinued and B would not. Yet at day 2, the day of the event, they were both off drug. Therefore, permanent discontinuation based on never restarting is not an appropriate approach – a defined time window for discontinuation is necessary. Discontinuation was defined as the cessation of OAC treatment for ≥7 consecutive days (whether or not OAC was restarted later), based on a consensus from the GARFIELD-AF Steering Committee which considered that the duration of most non-permanent treatment interruptions would continue for <1 week. OAC switching, without a ≥7 consecutive day suspension of treatment, was not considered

OAC discontinuation. This pre-specified criterion was applied to both those who survived and those who did not, to reduce bias in patient allocation to the discontinuation group. Thus, patients remained in the non-discontinuation group until discontinuation had continued for ≥7 consecutive days, without patient mortality. As a sensitivity analysis, the interruption of OAC treatment for at least 30 days was also assessed.

Endpoints of interest were the occurrence of the following combined outcomes as well as their individual components: death/stroke/systemic embolism (SE)/acute myocardial infarction (MI), death/stroke/SE, and death, stroke/SE and MI. All strokes included in this analysis were non-haemorrhagic. Haemorrhagic strokes were considered major bleeds.

*Statistical analysis*

Descriptive analyses were conducted in patients stratified according to whether they discontinued OAC therapy over the 2-year follow-up period. Continuous variables were presented as the medians and 75th and 25th percentiles or means with standard deviations. Only the first occurrence of each event was taken into account. In patients who discontinued OAC therapy, Kaplan-Meier event-free survival curves displayed the time to the event (or censoring) from the date of discontinuation.

Due to the complex nature of discontinuation, a method was developed to appropriately account for the confounding of baseline factors and factors occurring close to the time of discontinuation, and, in the case of treatment comparisons, censoring with treatment changes. Treatment-specific marginal structural Cox PH models estimated the effect of discontinuation (hazard ratio) on death, non-haemorrhagic stroke and SE, MI, or combined endpoints. Adjustments were made for baseline characteristics and time dependent variables, including bleeding left atrial appendage procedures, as well as MI and stroke (when not a component of the endpoint)[18]. Baseline factors considered were type of AF, diabetes, history of stroke or transient ischemic attack (TIA), SE, bleeding, hypertension, vascular disease, acute coronary syndrome, moderate-to-severe kidney disease, dementia, alcohol use, smoking status, body mass index, sex, age, race, heart rate, baseline systolic and diastolic blood pressures, care setting location and type, and country. Subject-specific, time-dependent weights used in fitting the treatment-specific marginal structural Cox PH model controlled for three sources of potential bias: non-randomized treatment, time-dependent confounding, and informative censoring (induced by censoring patients that either switch treatments or return to treatment after discontination). Supplemental Figure 1

displays the time to discontinuation by treatment, among patients that did not switch treatment prior to discontinuing. The interaction of OAC treatment type and discontinuation was non-significant for each endpoint considered, and thus was not included within the final model.

**Results**

Of 34,897 patients enrolled between May-2013 and Jul-2016, 8,595 did not receive OAC or had missing information, 2,420 started treatment during the follow-up period and were therefore excluded. The remaining 23,882 patients included 11,908 (49.9%) patients on VKA and 11,974 (50.1%) on DOACs (factor Xa inhibitor (FXaI): 9,228 (38.6%) and direct thrombin inhibitor (DTI): 2,746 (11.5%)) as their first anticoagulant treatment following AF diagnosis. Follow-up after discontinuation (number of days to death or last follow-up) was 511 days (interquartile range (IQR): 291-648). Overall, 3,114 patients (13.0%) discontinued OAC for ≥7 consecutive days. Discontinuation for patients treated with VKA, FXaI, and DTI occurred in 12.7%, 12.8%, and 15.4% of cases respectively (unadjusted). At least 95% of patients in both the discontinued and not-discontinued groups completed >700 days of follow-up.

Baseline characteristics are shown in Table 1. Patients who discontinued OAC tended to be younger, less likely to have diabetes, and more likely to have a history of bleeding and a history of stroke/TIA. A similar median $CHA_2DS_2$-VASc score and risk of bleeding according to the HAS-BLED score was observed in both groups. Prescription of anticoagulants at baseline was balanced between the two groups, though numerically patients who discontinued were more frequently prescribed a DTI.

The median time from initial anticoagulation to discontinuation was 182 days (IQR: 69-389). Many discontinuations occurred early after initiation of treatment: 38.2% within the first 4 months and 40.9% after 8 months (Figure 1). Of the patients who discontinued for ≥7 consecutive days, 77.9% remained off any OAC beyond 30 days. At the time of discontinuation, 93.9% of patients (n=2,925) had remained on the same OAC on which they were initiated on enrolment. In addition to OAC, antiplatelet therapy was used in 684 (22.0%) patients who discontinued treatment, versus 4,238 (20.4%) of those that did not.

Reason for discontinuation was recorded in 2,172 of cases. The decision to discontinue was most often made by the referring physician (51.0%) rather than the patient (18.5%). The decision for discontinuation was rarely end of planned treatment (6.2%), pregnancy or adverse events (3.5%), and cost of treatment or reimbursement (1.3%). In 35.4% of cases, 'other' or no reason was given by the physician.

Rates of discontinuation differed by country. The lowest rates were observed in India (2.7%), Egypt (3.3%) and Thailand (4.2%) and the highest rates were in the United States (21.2%), South Africa (22.1%) and Australia (28.3%) (Figure 2).

*Predictors of discontinuation*

As shown in Figure 3 and supplemental table S1 of the propensity model for discontinuation, the adjusted likelihood of discontinuing was significantly higher in Caucasian patients versus other races, patients with a history of bleeding, kidney disease, and/or coronary artery disease, paroxysmal (vs. persistent) AF, and in patients initiated by primary care physicians rather than cardiologists. Adjusted factors associated with a significantly lower risk of discontinuation were: increasing age, history of stroke or TIA, a history of acute coronary syndromes, diabetes mellitus, hypertension and permanent AF (compared to persistent AF). The adjusted likelihood of treatment discontinuation also trended toward lower rates in patients recruited by neurologists vs. cardiologists.

Within the model, all post-baseline factors such as bleeding (major, clinically relevant non-major bleed, and minor bleeding), left atrial appendage procedures, stroke/SE and MI were associated with a higher risk of discontinuation (Figure 3).

*Restarting OAC after discontinuation*

Of the 22,677 patients who survived to 1-year 18,528 (81.7%) remained on their initial OAC. At 2 years follow-up, 79.0% (14,516 of the 18,374 remaining patients) remained on their initial anticoagulant treatment. Overall, 1,415 of 3,114 patients (45.4%) who discontinued OAC therapy for ≥7 consecutive days restarted anticoagulation during follow-up. The median time to restarting antithrombotic therapy was 31 days (IQR 12-158). The majority returned to the same OAC used at the time of discontinuation. Of 665 patients who discontinued VKA, 509 (76.5%) restarted on VKA and 156 (23.5%) switched to a DOAC: FXaI in 116 patients (17.4%) and DTI in 40 patients (6.0%). Of 561 patients who discontinued FXaI, 481 (85.7%) returned to a FXaI, 25 (4.5%) were given DTI and 55 (9.8%) VKA. For the 189 patients who discontinued DTI, 116 (61.4%) restarted on DTI, 42 (22.2%) were given a FXaI and 31 (16.4%) VKA. A total of 1,160 (37%) of the 3,114 patients who discontinued were given antiplatelet therapy only. Of these, 1020 (87.9%) were on antiplatelet and OAC therapy at the time of discontinuation.

*Outcome analysis*

Among patients who discontinued OAC therapy, the majority of deaths was non-cardiovascular (52%) with 44.5% and 15.1% of those being due to malignancy or respiratory failure, respectively (Table 2). Cardiovascular-related deaths accounted for 27.9% of mortality within the discontinuation group, of which chronic heart failure (34.4%) was most common. In contrast, patients who did not discontinue OAC had a comparable proportion of cardiovascular and non-cardiovascular mortality (34.1 and 36.2%, respectively). Cumulative event free survival for selected outcomes over 2 years in patients who either persisted or discontinued OAC is shown in Figure 4a and 4b, respectively. All event types occurred more in patients that discontinued (unadjusted). Post discontinuation the median time from discontinuation to death was 153 days (IQR 50-348), to MI 174 days (IQR 67-289) and to ischemic stroke 79 days (IQR 32-220). The median time to stroke for those who discontinued VKAs or DOACs (censored for patients who switched drug prior to discontinuation) were similar (98 days [30-220] vs 98 days [35-335], respectively).

Relative to patients who remained on OAC, patients who discontinued OAC for ≥7 consecutive days had a higher risk of all events ($p<0.001$), with the exception of cardiovascular death (HR 1.37 [0.80-2.35]), including composite and individual endpoints: death/non-haemorrhagic stroke/SE/MI (HR 1.67 [1.35-2.08], death/non-haemorrhagic stroke/SE (HR 1.66 [1.31-2.09], death (HR 1.62 [1.25-2.09]), non-haemorrhagic stroke/SE (HR 2.21 [1.42-3.44]) and MI (HR 1.85 [1.09-3.13]) (Figure 5a). These results were confirmed by additional sensitivity analyses among patients who discontinued OAC ≥30-days (Figure 5b).

Figure 6 displays outcome data according to anticoagulation type (VKA vs. DOAC). The results, showing worse outcomes after OAC discontinuation, were consistent for both VKA and DOAC treated patients with no significant interactions (p for interactions range=0.145-0.778).

**Discussion**

The main finding of this large prospective real-world cohort was that patients with newly diagnosed AF who discontinued OAC treatment for ≥7 consecutive days had worse clinical outcome, with a higher chance of stroke/SE and MI. These results were confirmed using a discontinuation window of 30 days, an important observation as 77.9% of patients who stopped the drug for 7 days remained off drug beyond 30 days. Although not statistically significant, a similar trend was also observed for cardiovascular-related mortality, whereby patients who discontinued OAC therapy were at a higher risk. The increased risk for MI supports the potential role of OAC in the prevention of acute coronary syndromes.[19] In agreement with our study, other studies evaluating the relationship between OAC persistence and clinical outcomes have also suggested worsening clinical outcomes with poor OAC adherence[14, 20-25]. Many of these studies were retrospective in design, with small cohorts of patients, often from insurance or pharmacy databases[20, 21, 23, 24].

We found that the rate of OAC discontinuation (VKAs and DOACs) was 13.0%, with a median follow-up after discontinuation (number of days to death or last follow-up) of 511 days (IQR 291-648). Treatment persistence was achieved in 82% of patients by 1 year of follow-up and 79% by 2 years. Patients who discontinued OAC had differing demographic, geographical and clinical characteristics and experienced adverse outcomes more frequently. Type of OAC did not impact patient outcomes.

Discontinuation rates of patients in GARFIELD-AF were lower compared to other registry studies and randomized trials[5, 11-13], although in line with rates found in the recent ORBIT II registry [14]. One possible reason for the lower discontinuation rate in GARFIELD-AF is that it includes only newly diagnosed AF patients (of whom 94.0% were OAC naïve), possibly leading to higher patient motivation and closer follow-up[26]. However, discontinuations occurred more frequently during the early months of follow-up, becoming less prevalent at subsequent time points, as in previous studies[5, 9, 24]. Although GARFIELD-AF is a non-interventional study, participation may have buttressed anticoagulation persistence.

Notably, patients who discontinued also more frequently had concomitant renal dysfunction, which itself increases the rate of major bleeding in response to OACs[11, 27, 28]. Also paroxysmal AF was associated with higher discontinuation rates[29]. In contrast, lower discontinuation was observed in patients with a higher thrombotic risk and those with a higher motivation to take OACs such as those with a prior stroke/TIA, permanent AF, a history of acute

coronary syndrome or increasing age. We also observed lower discontinuation when OAC was initiated by cardiologists compared to primary care.

Marked geographical differences in discontinuation rates were found whereby the highest rates of discontinuation were observed in the United States and South Africa. Studies investigating OAC discontinuation rates have collectively revealed varying rates of discontinuation across countries. Many of these studies, however, have been small in size, each reported data from single countries, utilized different definitions of discontinuation, were investigated over short time-frames, or reported discontinuation rates differently [6, 11, 30-34]. Thus comparisons among countries are complex. Reports from the prospective GLORIA-AF registry provide discontinuation data for dabigatran by region but no country details: compared to Europe, discontinuation rates were higher in North-America and Asia, while rates within Latin America and the Middle East were notably lower [12]. In GARFIELD-AF, insurance status and health care setting may have played a role. Indeed socio-economic factors, and local health care related factors likely influence patient compliance [35].

In patients for whom cause of discontinuation was provided (64%), cessation was mainly due to physician (51.1%) and patient decision (17.5%). Bleeding, including minor bleeding, was associated with an increased rate of discontinuation, especially during the week prior to discontinuation. In addition to bleeding episodes, new thrombotic events (stroke, MI) as well as left atrial appendage closure procedures were often associated with OAC discontinuation. The latter are commonly associated as they are performed most frequently in patients with contraindications to OACs[36-39]. Certainly, left atrial appendage closure procedures have been demonstrated as non-inferior to OAC treatment for the prevention of stroke/SE, making it an attractive alternative for patients with OAC contraindications[40]. However, the absolute number of these procedures was low.

Discontinuation rates of VKAs are known to be high [5, 6, 41]. Several studies show that DOACs generally have lower discontinuation rates [11-13, 41] compared to VKA, with DTI showing higher discontinuation rates than Xa inhibitors [11] [7]. In GARFIELD-AF we observed a higher rate of DTI discontinuation compared to Xa inhibitors or VKA.

DOAC and VKA discontinuation have been previously associated with comparable rates of stroke and systemic embolism within 30-days of discontinuation[42]. Due to the short half-life of DOACs, discontinuation could lead to a ‘rebound phenomenon’, resulting in an increase in pro-coagulant markers and an early increase in stroke risk[43]. In GARFIELD-AF, the impact of type

of OAC discontinuation upon outcomes did not differ between those who discontinued DOACs or VKAs. In a study by Park et al., following abrupt DOAC discontinuation, the median time to stroke was reported to be 7 days (IQR 4-15)[43], although the number of patients was limited. In GARFIELD-AF, the median time to ischemic stroke was 79 days (IQR 32-220). The 2-year follow-up of GARFIELD-AF provides data regarding the long-term effects of OAC discontinuation and suggests that over time, there is no significant difference between DOAC and VKA discontinuation.

Increased all-cause mortality following discontinuation is an important finding to consider. Non-cardiovascular related mortality accounted for a substantial proportion of deaths within the discontinuation group compared to the non-discontinuation group. This likely reflects differences in the proportion of underlying or pre-existing comorbidities. Indeed, newly diagnosed non-valvular AF could itself represent a marker of worsening underlying conditions, both cardiovascular and non-cardiovascular[44-48]. Within the discontinuation group, the majority of deaths was attributable to malignancy. Furthermore, new cancer itself likely leads to OAC discontinuation in favour of parenteral treatment.

**Study strengths and limitations**

In observational research there is always a risk of bias, such as confounding by indication. To minimise this risk, we used marginal structural models, analysing baseline and time dependent variables. This approach is considered more reliable than a time dependent Cox proportional hazards model[18].

Due to the time dependent nature of this analysis, comparing event rates at a time point rather than overall hazard ratios between groups can only be descriptive. Uncaptured confounding factors may be present and the cause of missing data was not recorded. Additionally, a small proportion of 26 patients within the discontinuation group were initiated on heparin within at least 7 days of OAC discontinuation, although this small number of patients was negligible. Nevertheless, GARFIELD-AF is a global rigorously designed registry with a unique methodology and prospective follow-up of at least 2 years, with a significant rate of source data verification.[17] Therefore, significant underreporting is unlikely. The start and stop dates of treatment are exactly known, providing precise information on timing of treatment relative to outcomes. In addition, pharmacy data were not collected, and therefore treatment adherence could not be assessed.

**Clinical implications**

In this large prospective registry, discontinuation rates are lower than historically reported. However, the outcome analysis suggests that discontinuation of OAC treatment in these patients should be discouraged, especially if the reasons for discontinuation do not relate to persistent hazards for the patients. Patients should be counselled that most adverse events, especially minor bleeds, should not lead to permanent OAC discontinuation. In cases of major gastrointestinal or intracranial bleeds, it is preferable to restart OAC therapy after resolution of the bleeding episode[49, 50]. As recommended by the European Heart Rhythm Association, an integrated AF care program with active patient involvement should be implemented[2]. This need is especially important during the first year after treatment initiation when rates of discontinuation are highest.

**Conclusions**

In GARFIELD-AF, the rate of discontinuation in this mixed VKA-DOAC population was 13.0%. Patients who discontinued their OAC for ≥7 consecutive days had a greater risk of a clinically relevant adverse outcome. These data suggest that discontinuation of OAC therapy in patients with AF at risk for stroke should be discouraged unless persistent patients' hazards are identified.

**Declaration of Interests**

F Cools: Speaker fees from Boehringer-Ingelheim Pharma, Bayer AG, Pfizer and speaker fees and modest research grant from Daiichi-Sankyo Europe; Dana Johnson was supported by NIH grant T32 HL079896. AJ Camm: Personal fees from Bayer, personal fees from Boehringer Ingelheim, personal fees from Pfizer/BMS, personal fees from Daiichi Sankyo, outside the submitted work; JP Bassand: none; FWA Verheugt: Grants from Bayer Healthcare; personal fees from Bayer Healthcare, BMS/Pfizer, Daiichi-Sankyo, and Boehringer-Ingelheim; S Yang: None to disclose; A Tsiatis: None to disclose; DA Fitzmaurice: personal fees from BMS/Pfizer, Boehringer-Ingelheim, Daiichi Sankyo, and Bayer; SZ Goldhaber: Research grants from BiO2 Medical, Boehringer-Ingelheim, BMS, BTG EKOS, Daiichi, Janssen, NHLBI, Thrombosis Research Institute, Personal fee from Agile, Bayer, Boehringer-Ingelheim, BMS, Daiichi, Janssen, Portola, Zafgen. S Goto: Research funding from Sanofi, Pfizer, Ono, and Bristol-Myers Squibb; personal fee from Bayer and AstraZeneca; S Haas: Personal fees from Aspen, Bayer, BMS, Daiichi-Sankyo, Portola, Sanofi, outside the submitted work; F Misselwitz: Employee of Bayer

AG; AGG Turpie: Personal fees from Bayer Healthcare, Janssen Pharmaceutical Research & Development LLC, Astellas, Portola, Takeda; KAA Fox: grants from Bayer, Johnson and Johnson, and Astra Zeneca; personal fees from Bayer, Johnson and Johnson, Lilly, Astra Zeneca, and Sanofi/Regeneron; K Pieper: Consultant for Thrombosis Research Institute, AstraZeneca, and Bayer ; AK Kakkar: received grants from Bayer AG and Sanofi; personal fees from Bayer AG, Janssen, Pfizer, Sanofi, Verseon and Anthos Therapeutics

**Funding**

This work was supported by an unrestricted research grant from Bayer AG (Berlin, Germany) to the Thrombosis Research Institute (London, UK), which sponsors the GARFIELD-AF registry. The manuscript/work is supported by KANTOR CHARITABLE FOUNDATION for the Kantor-Kakkar Global Centre for Thrombosis Science. The funding source had no involvement in the data collection, data analysis, or data interpretation.

**Author Contributions**

All authors contributed to the concept, design and conduct of the study. F Cools wrote the manuscript. D Johnson and K Pieper conducted the statistical analysis. All authors contributed to data interpretation, critically reviewed the manuscript, and approved the manuscript. A Kakkar and G Kayani handled funding and supervised the registry.

**Acknowledgements**

We would like to thank the physicians, nurses, and patients involved in the GARFIELD-AF registry. Editorial support was provided by Rae Hobbs, Surekha Damineni, and Rebecca Watkin (Thrombosis Research Institute, London, UK).

## References


1 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. *Ann Intern Med*. 2007; **146**: 857-67. 10.7326/0003-4819-146-12-200706190-00007.

2 Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL, Group ESCSD. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). *Eur Heart J*. 2020. 10.1093/eurheartj/ehaa612.

3 Verheugt FWA, Gao H, Al Mahmeed W, Ambrosio G, Angchaisuksiri P, Atar D, Bassand JP, Camm AJ, Cools F, Eikelboom J, Kayani G, Lim TW, Misselwitz F, Pieper KS, van Eickels M, Kakkar AK, Investigators G-A. Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry. *Eur Heart J*. 2018; **39**: 464-73. 10.1093/eurheartj/ehx730.

4 Nieuwlaat R, Capucci A, Lip GY, Olsson SB, Prins MH, Nieman FH, Lopez-Sendon J, Vardas PE, Aliot E, Santini M, Crijns HJ. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. *Eur Heart J*. 2006; **27**: 3018-26. 10.1093/eurheartj/ehl015.

5 Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, Singer DE. Warfarin discontinuation after starting warfarin for atrial fibrillation. *Circ Cardiovasc Qual Outcomes*. 2010; **3**: 624-31. 10.1161/CIRCOUTCOMES.110.937680.

6 Spivey CA, Qiao Y, Liu X, Mardekian J, Parker RB, Phatak H, Claflin AB, Kachroo S, Abdulsattar Y, Chakrabarti A, Wang J. Discontinuation/Interruption of Warfarin Therapy in Patients with Nonvalvular Atrial Fibrillation. *J Manag Care Spec Pharm*. 2015; **21**: 596-606. 10.18553/jmcp.2015.21.7.596.

7 Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, Committee R-LS, Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med*. 2009; **361**: 1139-51. 10.1056/NEJMoa0905561.

8 Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM, Investigators EA-T. Edoxaban versus warfarin in patients with atrial fibrillation. *N Engl J Med*. 2013; **369**: 2093-104. 10.1056/NEJMoa1310907.

9 Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ,

Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, Committees A, Investigators. Apixaban versus warfarin in patients with atrial fibrillation. *N Engl J Med*. 2011; **365**: 981-92. 10.1056/NEJMoa1107039.

10 Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, Investigators RA. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *N Engl J Med*. 2011; **365**: 883-91. 10.1056/NEJMoa1009638.

11 Beyer-Westendorf J, Ehlken B, Evers T. Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation. *Europace*. 2016; **18**: 1150-7. 10.1093/europace/euv421.

12 Paquette M, Riou Franca L, Teutsch C, Diener HC, Lu S, Dubner SJ, Ma CS, Rothman KJ, Zint K, Halperin JL, Huisman MV, Lip GYH, Nieuwlaat R. Persistence With Dabigatran Therapy at 2 Years in Patients With Atrial Fibrillation. *J Am Coll Cardiol*. 2017; **70**: 1573-83. 10.1016/j.jacc.2017.07.793.

13 Raparelli V, Proietti M, Cangemi R, Lip GY, Lane DA, Basili S. Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants. *Thromb Haemost*. 2017; **117**: 209-18. 10.1160/TH16-10-0757.

14 Jackson LR, 2nd, Kim S, Blanco R, Thomas L, Ansell J, Fonarow GC, Gersh BJ, Go AS, Kowey PR, Mahaffey KW, Hylek EM, Peterson ED, Piccini JP, Outcomes Registry for Better Informed Treatment of Atrial F, II. Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: Results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). *Am Heart J*. 2020; **226**: 85-93. 10.1016/j.ahj.2020.04.016.

15 Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. *Lancet*. 2014; **383**: 955-62. 10.1016/S0140-6736(13)62343-0.

16 Kakkar AK, Mueller I, Bassand JP, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Hacke W, Lip GY, Mantovani LG, Verheugt FW, Jamal W, Misselwitz F, Rushton-Smith S, Turpie AG. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). *Am Heart J*. 2012; **163**: 13-9 e1. 10.1016/j.ahj.2011.09.011.

17 Fox KAA, Gersh BJ, Traore S, John Camm A, Kayani G, Krogh A, Shweta S, Kakkar AK, Investigators G-A. Evolving quality standards for large-scale registries: the GARFIELD-AF experience. *Eur Heart J Qual Care Clin Outcomes*. 2017; **3**: 114-22. 10.1093/ehjqcco/qcw058.

18 Yang S, Tsiatis AA, Blazing M. Modeling survival distribution as a function of time to treatment discontinuation: A dynamic treatment regime approach. *Biometrics*. 2018; **74**: 900-9. 10.1111/biom.12845.

19 Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez-Jaramillo P, O'Donnell M, Kakkar AK, Fox KAA, Parkhomenko AN, Ertl G, Stork S, Keltai M, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim JH, Tonkin AM, Lewis BS, Felix C, Yusoff K, Steg PG, Metsarinne KP, Cook Bruns N, Misselwitz F, Chen E, Leong D, Yusuf S, Investigators C. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. *N Engl J Med*. 2017; **377**: 1319-30. 10.1056/NEJMoa1709118.

20 Borne RT, O'Donnell C, Turakhia MP, Varosy PD, Jackevicius CA, Marzec LN, Masoudi FA, Hess PL, Maddox TM, Ho PM. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration. *BMC Cardiovasc Disord*. 2017; **17**: 236. 10.1186/s12872-017-0671-6.

21 Gallego P, Roldan V, Marin F, Romera M, Valdes M, Vicente V, Lip GY. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. *Thromb Haemost*. 2013; **110**: 1189-98. 10.1160/TH13-07-0556.

22 Jackevicius CA, Tsadok MA, Essebag V, Atzema C, Eisenberg MJ, Tu JV, Lu L, Rahme E, Ho PM, Turakhia M, Humphries KH, Behlouli H, Zhou L, Pilote L. Early non-persistence with dabigatran and rivaroxaban in patients with atrial fibrillation. *Heart*. 2017; **103**: 1331-8. 10.1136/heartjnl-2016-310672.

23 Rivera-Caravaca JM, Roldan V, Esteve-Pastor MA, Valdes M, Vicente V, Lip GYH, Marin F. Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients. *Thromb Haemost*. 2017; **117**: 1448-54. 10.1160/TH16-12-0961.

24 Shore S, Carey EP, Turakhia MP, Jackevicius CA, Cunningham F, Pilote L, Bradley SM, Maddox TM, Grunwald GK, Baron AE, Rumsfeld JS, Varosy PD, Schneider PM, Marzec LN, Ho PM. Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration. *Am Heart J*. 2014; **167**: 810-7. 10.1016/j.ahj.2014.03.023.

25 Yao X, Abraham NS, Alexander GC, Crown W, Montori VM, Sangaralingham LR, Gersh BJ, Shah ND, Noseworthy PA. Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation. *J Am Heart Assoc*. 2016; **5**. 10.1161/JAHA.115.003074.

26 Manzoor BS, Lee TA, Sharp LK, Walton SM, Galanter WL, Nutescu EA. Real-World Adherence and Persistence with Direct Oral Anticoagulants in Adults with Atrial Fibrillation. *Pharmacotherapy*. 2017; **37**: 1221-30. 10.1002/phar.1989.

27 Jun M, James MT, Manns BJ, Quinn RR, Ravani P, Tonelli M, Perkovic V, Winkelmayer WC, Ma Z, Hemmelgarn BR, Alberta Kidney Disease N. The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study. *BMJ*. 2015; **350**: h246. 10.1136/bmj.h246.

28 Gutierrez OM. Risks of anticoagulation in patients with chronic kidney disease and atrial fibrillation: More than just bleeding? *Res Pract Thromb Haemost*. 2019; **3**: 147-8. 10.1002/rth2.12188.

29 Aronis KN, Thigpen JL, Tripodis Y, Dillon C, Forster K, Henault L, Quinn EK, Berger PB, Limdi NA, Hylek EM. Paroxysmal atrial fibrillation and the hazards of under-treatment. *Int J Cardiol*. 2016; **202**: 214-20. 10.1016/j.ijcard.2015.09.006.

30 Martinez C, Katholing A, Freedman SB. Adverse prognosis of incidentally detected ambulatory atrial fibrillation. A cohort study. *Thromb Haemost*. 2014; **112**: 276-86. 10.1160/TH4-04-0383.

31 Ruigomez A, Vora P, Balabanova Y, Brobert G, Roberts L, Fatoba S, Fernandez O, Garcia Rodriguez LA. Discontinuation of non-Vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation: a population-based cohort study using primary care data from The Health Improvement Network in the UK. *BMJ Open*. 2019; **9**: e031342. 10.1136/bmjopen-2019-031342.

32 Kachroo S, Hamilton M, Liu X, Pan X, Brixner D, Marrouche N, Biskupiak J. Oral anticoagulant discontinuation in patients with nonvalvular atrial fibrillation. *Am J Manag Care*. 2016; **22**: e1-8.

33 Forslund T, Wettermark B, Hjemdahl P. Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation. *Eur J Clin Pharmacol*. 2016; **72**: 329-38. 10.1007/s00228-015-1983-z.

34 Maura G, Billionnet C, Alla F, Gagne JJ, Pariente A. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases. *Pharmacotherapy*. 2018; **38**: 6-18. 10.1002/phar.2046.

35 Hernandez I, He M, Chen N, Brooks MM, Saba S, Gellad WF. Trajectories of Oral Anticoagulation Adherence Among Medicare Beneficiaries Newly Diagnosed With Atrial Fibrillation. *J Am Heart Assoc*. 2019; **8**: e011427. 10.1161/JAHA.118.011427.

36 Zweiker D, Sieghartsleitner R, Fiedler L, Toth GG, Luha O, Stix G, Gabriel H, Vock P, Lileg B, Strouhal A, Delle-Karth G, Pfeffer M, Aichinger J, Tkalec W, Steinwender C, Sihorsch K, Binder RK, Rammer M, Barbieri F, Mueller S, Verheyen N, Ablasser K, Zirlik A, Scherr D. Indications and Outcome in Patients Undergoing Left Atrial Appendage Closure-The Austrian LAAC Registry. *J Clin Med*. 2020; **9**. 10.3390/jcm9103274.

37 Boersma LV, Ince H, Kische S, Pokushalov E, Schmitz T, Schmidt B, Gori T, Meincke F, Protopopov AV, Betts T, Foley D, Sievert H, Mazzone P, De Potter T, Vireca E, Stein K, Bergmann MW, Investigators E. Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial. *Heart Rhythm*. 2017; **14**: 1302-8. 10.1016/j.hrthm.2017.05.038.

38 Pison L, Potpara TS, Chen J, Larsen TB, Bongiorni MG, Blomstrom-Lundqvist C, Scientific Initiative Committee EHRA. Left atrial appendage closure-indications, techniques, and outcomes: results of the European Heart Rhythm Association Survey. *Europace*. 2015; **17**: 642-6. 10.1093/europace/euv069.

39 Reddy VY, Mobius-Winkler S, Miller MA, Neuzil P, Schuler G, Wiebe J, Sick P, Sievert H. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). *J Am Coll Cardiol*. 2013; **61**: 2551-6. 10.1016/j.jacc.2013.03.035.

40 Osmancik P, Herman D, Neuzil P, Hala P, Taborsky M, Kala P, Poloczek M, Stasek J, Haman L, Branny M, Chovancik J, Cervinka P, Holy J, Kovarnik T, Zemanek D, Havranek S, Vancura V, Opatrny J, Peichl P, Tousek P, Lekesova V, Jarkovsky J, Novackova M, Benesova K, Widimsky P, Reddy VY, Investigators P-T. Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation. *J Am Coll Cardiol*. 2020; **75**: 3122-35. 10.1016/j.jacc.2020.04.067.

41 Obamiro KO, Chalmers L, Bereznicki LR. A Summary of the Literature Evaluating Adherence and Persistence with Oral Anticoagulants in Atrial Fibrillation. *Am J Cardiovasc Drugs*. 2016; **16**: 349-63. 10.1007/s40256-016-0171-6.

42 Patel MR, Hellkamp AS, Lokhnygina Y, Piccini JP, Zhang Z, Mohanty S, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Becker RC, Nessel CC, Berkowitz SD, Califf RM, Fox KA, Mahaffey KW. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). *J Am Coll Cardiol*. 2013; **61**: 651-8. 10.1016/j.jacc.2012.09.057.

43 Park JH, Han SW, Lee KY, Choi HY, Cheon K, Cho HJ, Jung YH, Park HJ, Nam HS, Heo JH, Lee HS, Saposnik G, Kim YD. Impact of Non-vitamin K Antagonist Oral Anticoagulant Withdrawal on Stroke Outcomes. *Front Neurol*. 2018; **9**: 1095. 10.3389/fneur.2018.01095.

44 Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. *Physiol Rev*. 2011; **91**: 265-325. 10.1152/physrev.00031.2009.

45 McManus DD, Rienstra M, Benjamin EJ. An update on the prognosis of patients with atrial fibrillation. *Circulation*. 2012; **126**: e143-6. 10.1161/CIRCULATIONAHA.112.129759.

46 Chamberlain AM, Redfield MM, Alonso A, Weston SA, Roger VL. Atrial fibrillation and mortality in heart failure: a community study. *Circ Heart Fail*. 2011; **4**: 740-6. 10.1161/CIRCHEARTFAILURE.111.962688.

47 Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, D'Agostino RB, Murabito JM, Kannel WB, Benjamin EJ. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. *Circulation*. 2003; **107**: 2920-5. 10.1161/01.CIR.0000072767.89944.6E.

48 Kirchhof P, Lip GY, Van Gelder IC, Bax J, Hylek E, Kaab S, Schotten U, Wegscheider K, Boriani G, Brandes A, Ezekowitz M, Diener H, Haegeli L, Heidbuchel H, Lane D, Mont L, Willems S, Dorian P, Aunes-Jansson M, Blomstrom-Lundqvist C, Borentain M, Breitenstein S, Brueckmann M, Cater N, Clemens A, Dobrev D, Dubner S, Edvardsson NG, Friberg L, Goette A, Gulizia M, Hatala R, Horwood J, Szumowski L, Kappenberger L, Kautzner J, Leute A, Lobban T, Meyer R, Millerhagen J, Morgan J, Muenzel F, Nabauer M, Baertels C, Oeff M, Paar D, Polifka J, Ravens U, Rosin L, Stegink W, Steinbeck G, Vardas P, Vincent A, Walter M, Breithardt G, Camm AJ. Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. *Europace*. 2012; **14**: 8-27. 10.1093/europace/eur241.

49 Nielsen PB, Larsen TB, Skjoth F, Gorst-Rasmussen A, Rasmussen LH, Lip GY. Restarting Anticoagulant Treatment After Intracranial Hemorrhage in Patients With Atrial Fibrillation and the Impact on Recurrent Stroke, Mortality, and Bleeding: A Nationwide Cohort Study. *Circulation*. 2015; **132**: 517-25. 10.1161/CIRCULATIONAHA.115.015735.

50 Staerk L, Lip GY, Olesen JB, Fosbol EL, Pallisgaard JL, Bonde AN, Gundlund A, Lindhardt TB, Hansen ML, Torp-Pedersen C, Gislason GH. Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study. *BMJ*. 2015; **351**: h5876. 10.1136/bmj.h5876.

**Figure legends**

**Figure 1**. Months from start of treatment to discontinuation.

**Figure 2**. Percentages of discontinuation rates by country.

**Figure 3.** Adjusted hazard ratios for discontinuation with 95% CIs after AF diagnosis between patients who did and did not discontinue anticoagulation. Higher rates were seen in patients with a history of bleeding, all stages of kidney failure, as well as all post-baseline factors (all types of bleeding, stroke/SE, MI and left atrial appendage procedures). Lower discontinuation was seen with increasing age, when a history of stroke/TIA and in permanent AF.

**Figure 4a**. Cumulative event free survival for selected endpoints of patients who did not discontinue during follow-up. Follow-up starts at enrolment and is truncated at 2 years.

**Figure 4b**. Cumulative event free survival for selected endpoints of patients who discontinued during follow-up. Follow-up starts at the time of discontinuation and is truncated at 2 years.

**Figure 5**. Adjusted hazard ratios for outcome events with 95% CIs over 2 years following AF diagnosis for patients who discontinued anticoagulation for (A) ≥7 consecutive days and (B) ≥30 consecutive days, vs those who did not discontinue anticoagulation (reference group). CI: confidence interval, MI: myocardial infarction, SE: systemic embolism,

**Figure 6.** Adjusted hazard ratios for outcome events in patients treated with DOAC or VKA over 2 years following AF-diagnosis who discontinued anticoagulation vs those who did not discontinue anticoagulation (reference group). There were no significant interactions between discontinuation and type of anticoagulant (all $p > 0.14$).

**Table 1**. Baseline characteristics of patients that discontinued OAC treatment vs. those that did not.

| **Baseline characteristics** | **Permanent discontinuation (n=3,114)** | **No discontinuation (n=20,768)** |
|---|---|---|
| Male, n (%) | 1,827 (58.7) | 11,307 (54.4) |
| Age, median (IQR) | 70 (61, 78) | 72 (64, 79) |
| <65 years, n (%) | 1,032 (33.1) | 5,257 (25.3) |
| 65-74 years, n (%) | 984 (31.6) | 7,249 (34.9) |
| ≥75 years, n (%) | 1,098 (35.3) | 8,262 (39.8) |
| Race, n (%) | | |
| Caucasian | 2,235 (71.8) | 13,221 (63.7) |
| Hispanic/Latino | 120 (3.9) | 1,321 (6.4) |
| Afro-Caribbean | 10 (0.3) | 131 (0.6) |
| Asian (not Chinese) | 553 (17.8) | 4,796 (23.1) |
| Chinese | 51 (1.6) | 504 (2.4) |
| Mixed/other/unspecified | 145 (4.7) | 795 (3.8) |
| Body mass index, median (IQR) | 27 (24, 31) | 27 (24, 31) |
| Hypertension, n (%) | 2,377 (76.7) | 16,159 (77.1) |
| Hypercholesterolemia, n (%) | 1,635 (42.3) | 9,523 (42.5) |
| Diabetes, n (%) | 649 (20.8) | 4,901 (23.6) |
| Smoking, n (%) | | |
| Never smoked | 1,820 (63.3) | 12,356 (65.2) |
| Ex-smoker | 749 (26.1) | 4,675 (24.7) |
| Current smokes | 305 (10.6) | 1,920 (10.1) |
| Alcohol consumption, n (%) | | |
| Abstinent/Light | 2,236 (85.8) | 15,442 (88.4) |
| Moderate/Heavy | 370 (14.2) | 2,024 (11.6) |
| Type of atrial fibrillation , (%) | | |
| Permanent | 283 (9.1) | 3,004 (14.5) |
| Persistent | 504 (16.2) | 3,507 (16.9) |

| | | |
|---|---|---|
| Paroxysmal | 879 (28.2) | 5,565 (26.8) |
| Unclassified | 1,448 (46.5) | 8,692 (41.9) |
| Care setting at diagnosis, n (%) | | |
| Hospital | 1,719 (55.2) | 10,935 (52.7) |
| Office | 969 (31.2) | 7,582 (36.5) |
| AC clinic/thrombosis centre | 9 (0.3) | 99 (0.5) |
| Emergency room | 417 (13.4) | 2,152 (10.4) |
| Heart failure, n (%) | 684 (22.0) | 4,650 (22.4) |
| Coronary artery disease, n (%) | 672 (21.6) | 4,205 (20.3) |
| Vascular disease, n (%) | 287 (9.2) | 2,485 (12.0) |
| Stroke/TIA, n (%) | 1,719 (55.2) | 10,935 (52.7) |
| Systemic embolization, n (%) | 16 (0.5) | 174 (0.8) |
| Bleeding history, n (%) | 88 (2.8) | 338 (1.6) |
| Chronic kidney disease*, n (%) | 416 (13.8) | 2,198 (11.1) |
| $CHA_2DS_2$-VASc, mean (SD) | 3.1 (1.7) | 3.4 (1.5) |
| $CHA_2DS_2$-VASc, median (IQR) | 3 (2.0-4.0) | 3 (2.0-4.0) |
| HAS-BLED, mean (SD) | 1.3 (0.9) | 1.3 (0.9) |
| HAS-BLED, median (IQR) | 1.0 (1.0-2.0) | 1.0 (1.0-2.0) |
| Baseline Treatment, n (%) | | |
| VKA | 1,123 (36.1) | 7,908 (38.1) |
| VKA+AP | 388 (12.5) | 2,489 (12.0) |
| FXaI | 959 (30.8) | 6,673 (32.1) |
| FXaI+AP | 221 (7.1) | 1,375 (6.6) |
| DTI | 348 (11.2) | 1,949 (9.4) |
| DTI+AP | 75 (2.4) | 374 (1.8) |

* Chronic kidney disease (stage 3-5),

SD: standard deviation, IQR: inter-quartile range, AC clinic: anticoagulation clinic, TIA: transient ischemic attack, VKA: vitamin K antagonist, AP: antiplatelet, FXaI: factor Xa inhibitor, DTI: direct thrombin inhibitor

**Table 2.** Distribution of cause of death by discontinuation status.

| Cause of death | Discontinued (229 deaths) N (%) | Did not discontinue (1,424 deaths) N (%) |
|---|---|---|
| **Non-cardiovascular death** | **119 (52.0)** | **515 (36.2)** |
| **Cardiovascular death** | **64 (27.9)** | **485 (34.1)** |
| **Other/Unknown causes of death** | **46 (20.1)** | **424 (29.8)** |
| | | |
| **Non-cardiovascular causes[1]** | | |
| Malignancy | 53 (44.5) | 148 (28.7) |
| Respiratory failure | 18 (15.1) | 85 (16.5) |
| Sepsis | 15 (12.6) | 51 (9.9) |
| Infection | 9 (7.6) | 53 (10.3) |
| Renal disease | 6 (5.0) | 30 (5.8) |
| Accidental/trauma | 1 (0.8) | 21 (4.1) |
| Liver failure | 3 (2.5) | 8 (1.6) |
| Suicide | 0 (0.0) | 4 (0.8) |
| Other/Unknown non-cardiovascular | 14 (11.8) | 115 (22.3) |
| **Cardiovascular causes[2]** | | |
| Congestive heart failure | 22 (34.4) | 184 (37.9) |
| Sudden or unwitnessed death | 12 (18.7) | 71 (14.6) |
| Myocardial infarction | 4 (6.3) | 49 (10.1) |
| Non-haemorrhagic stroke | 12 (18.7) | 42 (8.7) |
| Intracranial haemorrhage | 1 (1.6) | 24 (5.0) |
| Pulmonary embolism | 2 (3.1) | 22 (4.5) |
| Atherosclerotic vascular disease | 1 (1.6) | 14 (2.9) |
| Dysrhythmia | 2 (3.1) | 12 (2.5) |
| Directly related to revascularisation | 0 (0.0) | 2 (0.4) |
| Other/Unknown cardiovascular | 8 (12.5) | 65 (13.4) |

[1]Percentages calculates among patients deceased of non-cardiovascular causes;

[2]Percentages calculates among patients deceased of cardiovascular causes.




jth_15415_f1.tif




jth_15415_f2.tif




jth_15415_f3.tif




jth_15415_f4a.tif




jth_15415_f4b.tif




jth_15415_f5.tif




jth_15415_f6.tif